Atlas Trials

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Clinical trial NCT02097225 · TERMINATED

Trial details

NCT number
NCT02097225
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid NeoplasmMetastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Solid Neoplasm
Start date
2014-05-29
Primary completion
2019-03-31
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.